The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Rheumatoid Arthritis Patients in Remission Withdrawing from TNF Inhibition Show Flare Increases
New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.
Ryan DeMasi, MD: Long-Term Safety, Efficacy of Risankizumab in Patients with Psoriatic Arthritis
The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time.
Ryan DeMasi, MD: Upadacitinib Monotherapy Compared with Methotrexate in Rheumatoid Arthritis
Ryan DeMasi, MD, explained despite the patients' shorter disease duration, they exhibited severe symptoms, prompting a more aggressive early intervention approach using treatment with upadacitinib.
Racial, Ethnic Disparities Observed in Patients with Psoriatic Arthritis
Patients with PsA in the self-reported racial and ethnic minority were less likely to be diagnosed within 12 months of symptom onset and were more frequently uninsured compared with White patients .
Damini Jawaheer, PhD: Biomarkers may Predict Disease Severity in Pregnant Patients with RA
Jawaheer and her team used pre-pregnancy data to determine whether there are gene expression biomarkers at the pre-pregnancy baseline that can predict improvement or worsening during pregnancy in patients with rheumatoid arthritis.
Don't Miss a Beat: SELECT, DAPA-MI, & AHA 2023
November 13th 2023In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.
History of Hepatocellular Carcinoma Increases Risk of Liver-Related Mortality After SVR
November 13th 2023Results from this prospective study in Japan found older age, history of hepatocellular carcinoma, and decreased albumin level at SVR were significantly associated with liver-related mortality after SVR.